NO20051242L - Blandinger for inhibering av protein kinase C alfa for behandling av Diabetes mellitus og kardiovaskulaere sykdommer - Google Patents

Blandinger for inhibering av protein kinase C alfa for behandling av Diabetes mellitus og kardiovaskulaere sykdommer

Info

Publication number
NO20051242L
NO20051242L NO20051242A NO20051242A NO20051242L NO 20051242 L NO20051242 L NO 20051242L NO 20051242 A NO20051242 A NO 20051242A NO 20051242 A NO20051242 A NO 20051242A NO 20051242 L NO20051242 L NO 20051242L
Authority
NO
Norway
Prior art keywords
treatment
protein kinase
diabetes mellitus
activity
cardiovascular diseases
Prior art date
Application number
NO20051242A
Other languages
English (en)
Norwegian (no)
Inventor
Jan Menne
Hermann Haller
Original Assignee
Phenos Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenos Gmbh filed Critical Phenos Gmbh
Publication of NO20051242L publication Critical patent/NO20051242L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
NO20051242A 2002-09-24 2005-03-10 Blandinger for inhibering av protein kinase C alfa for behandling av Diabetes mellitus og kardiovaskulaere sykdommer NO20051242L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10244453A DE10244453A1 (de) 2002-09-24 2002-09-24 Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
PCT/DE2003/003165 WO2004028516A2 (de) 2002-09-24 2003-09-23 Zusammensetzungen zur hemmung der proteinkinase c alpha zur behandlung von diabetes mellitus und kardiovaskulärer erkrankungen

Publications (1)

Publication Number Publication Date
NO20051242L true NO20051242L (no) 2005-06-01

Family

ID=31969524

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051242A NO20051242L (no) 2002-09-24 2005-03-10 Blandinger for inhibering av protein kinase C alfa for behandling av Diabetes mellitus og kardiovaskulaere sykdommer

Country Status (19)

Country Link
US (2) US20050250719A1 (pl)
EP (2) EP1545560B1 (pl)
JP (1) JP2006503841A (pl)
KR (1) KR20050059180A (pl)
CN (1) CN1684694A (pl)
AT (1) ATE475422T1 (pl)
AU (1) AU2003280288B2 (pl)
CA (1) CA2499818A1 (pl)
DE (3) DE10244453A1 (pl)
DK (1) DK1545560T3 (pl)
EA (1) EA007926B1 (pl)
ES (1) ES2356286T3 (pl)
IS (1) IS7777A (pl)
MX (1) MXPA05002930A (pl)
NO (1) NO20051242L (pl)
NZ (1) NZ538857A (pl)
PL (1) PL374829A1 (pl)
UA (1) UA88257C2 (pl)
WO (1) WO2004028516A2 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
CA2538999A1 (en) * 2003-09-19 2005-03-31 Children's Hospital Medical Center Regulation of cardiac contractility and heart failure propensity
US8258105B2 (en) * 2003-10-07 2012-09-04 Isis Pharmaceuticals, Inc. Antisense oligonucleotides optimized for kidney targeting
US9144594B2 (en) * 2005-11-08 2015-09-29 University Of Miami Cathepsin L mediated diseases and associated methods and products
AU2006321727A1 (en) * 2005-12-09 2007-06-14 Metaproteomics, Llc Protein kinase modulation by hops and Acacia products
WO2007108727A1 (en) * 2006-03-22 2007-09-27 Leangene Ab Method for monitoring the effect of compounds on foxc2 expression
KR20120091267A (ko) 2007-01-31 2012-08-17 바이오석세스 바이오텍 컴퍼니 포르볼 에스테르 조성물과 그의 사용 방법
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US10369222B2 (en) 2012-01-18 2019-08-06 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US11696908B2 (en) 2007-01-31 2023-07-11 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9636317B2 (en) 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US11564901B2 (en) 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
EP1982722A1 (en) * 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
WO2011041584A2 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
US9550722B2 (en) 2012-01-18 2017-01-24 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbal esters for the treatment of stroke
US10099996B2 (en) 2012-01-18 2018-10-16 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
KR102102677B1 (ko) * 2012-01-18 2020-04-22 바이오석세스 바이오텍 컴퍼니 리미티드 포르볼 에스테르의 조성물
US20150079111A1 (en) * 2012-06-05 2015-03-19 Jonas Axelsson Mechanism, diagnostic, and treatments for complications of renal failure
WO2013190582A1 (en) 2012-06-22 2013-12-27 Gentium S.P.A. Euglobulin-based method for determining the biological activity of defibrotide
TWI750481B (zh) * 2013-01-18 2021-12-21 美商華鴻新藥股份有限公司 用於中風治療之巴豆酯組成物及使用方法
TWI687217B (zh) * 2014-01-10 2020-03-11 華鴻新藥股份有限公司 用於中風治療之巴豆酯組成物及使用方法
EP3099312B1 (en) 2014-01-29 2018-12-05 Université de Strasbourg New target for diabetes treatment and prevention
CN106458993A (zh) * 2014-04-14 2017-02-22 阿尔维纳斯股份有限公司 基于酰亚胺的蛋白水解调节剂和相关使用方法
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
WO2017004151A1 (en) 2015-06-29 2017-01-05 Regents Of The University Of Minnesota Anti-apobec3 antibodies and methods of making and using
EP3421485A1 (en) 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
CN111386240A (zh) * 2017-09-29 2020-07-07 安全工程有限责任公司 具有直流电源的提升机系统
RU2765117C2 (ru) * 2019-09-24 2022-01-25 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" Применение натриевой соли диэтилового эфира 4-оксо-1,4-дигидропиразоло[5,1-с]-1,2,4-триазин-3,8-дикарбоновой кислоты, моногидрата в качестве средства лечения и профилактики поздних осложнений сахарного диабета
WO2022092884A1 (ko) * 2020-10-29 2022-05-05 가톨릭관동대학교산학협력단 13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
HUT64837A (en) * 1990-10-01 1994-03-28 Brigham & Womens Hospital Preparatives of beta-carotine and those of vitamine e having ulceration inhibiting effect
HUT64295A (en) * 1990-11-02 1993-12-28 Sphinx Pharma Corp Method for producing bis-(hydroxy-alkyl-amino)-anthraquinone derivatives as well as pharmaceutical preparatives containing them
AU1783092A (en) * 1991-04-08 1992-11-02 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Inhibitors of protein kinase c function
EP0817627B1 (en) 1993-12-23 2005-03-09 Eli Lilly And Company Protein kinase c inhibitors
US5491242A (en) 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5710145A (en) * 1995-11-20 1998-01-20 Eli Lilly And Company Protein kinase C inhibitor
WO1997041127A1 (en) * 1996-05-01 1997-11-06 Eli Lilly And Company Halo-substituted protein kinase c inhibitors
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
DE19740384A1 (de) * 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
CA2538999A1 (en) * 2003-09-19 2005-03-31 Children's Hospital Medical Center Regulation of cardiac contractility and heart failure propensity

Also Published As

Publication number Publication date
CN1684694A (zh) 2005-10-19
DE10393825D2 (de) 2005-08-11
NZ538857A (en) 2010-10-29
PL374829A1 (pl) 2005-10-31
DE10244453A1 (de) 2004-04-01
DK1545560T3 (da) 2010-11-22
CA2499818A1 (en) 2004-04-08
EP2338498A1 (de) 2011-06-29
ES2356286T3 (es) 2011-04-06
UA88257C2 (ru) 2009-10-12
EA200500529A1 (ru) 2005-08-25
EP1545560B1 (de) 2010-07-28
EP1545560A2 (de) 2005-06-29
EA007926B1 (ru) 2007-02-27
DE50312935D1 (de) 2010-09-09
ATE475422T1 (de) 2010-08-15
AU2003280288B2 (en) 2008-08-28
US20090191194A1 (en) 2009-07-30
WO2004028516A2 (de) 2004-04-08
US20050250719A1 (en) 2005-11-10
AU2003280288A1 (en) 2004-04-19
IS7777A (is) 2005-03-30
MXPA05002930A (es) 2005-09-30
KR20050059180A (ko) 2005-06-17
WO2004028516A3 (de) 2004-11-11
JP2006503841A (ja) 2006-02-02

Similar Documents

Publication Publication Date Title
NO20051242L (no) Blandinger for inhibering av protein kinase C alfa for behandling av Diabetes mellitus og kardiovaskulaere sykdommer
NO20053837L (no) Farmasoytisk blanding for profylakse eller behandling av kardiovaskulaere-, kardiopulmonaere-, pulmonaere- eller nyresykdommer.
NO20044534L (no) Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer
RS51449B (sr) Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija
NO20060864L (no) Farmasoytisk sammensetning omfattende en kombinasjon av metformin og et statin
DK1349843T3 (da) Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer
NO20062292L (no) Fremgangsmate for behandling av transplantasjonsavstoting
BR0210167A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto
WO2003044015A3 (en) Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
ATE386715T1 (de) Modulatoren des peroxisomproliferatoraktivierten rezeptors
NO20032861L (no) Heteroarylurea nevropeptid Y Y5-reseptorantagonister
ATE307604T1 (de) Verwendung von ace inhibitoren zur prophylaxe von kongestivem herzversagen
NO20052159L (no) Substituert (tiazol-2-yl)-amid eller sulfonamid som glykokinase-aktivatorer nyttige ved behandling av type 2 diabetes.
BR0009563A (pt) Inibidores de ap2 de bifenilas contendo heterocìclico e método
MY136632A (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
PL376213A1 (pl) Kompozycja farmaceutyczna do zapobiegania lub leczenia chorób sercowo-naczyniowych, sercowo-płucnych, płucnych lub nerek
CA2341638A1 (en) Use of a midkine inhibitor
NO20012831L (no) Diazepinoindoler for behandling av kronisk obstruktiv lungesykdom
NO20043286L (no) Piperidinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
SE0201939D0 (sv) New combination
HK1097406A1 (en) Selective peroxisome proliferator activated receptor modulators
NZ535199A (en) Use of an inhibitor or antagonist against tissue factor
UA83265C2 (ru) Селективные модуляторы рецепторов, которые активируются пролифераторами пероксисом
TH77756A (th) สารประกอบอินทรีย์
TH64458A (th) ตัวยับยั้ง Rho-Kinase

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application